Risk Factors Update Summary

• Failure to achieve commercial success of iDose TR could materially impact business. Downturns in general economic conditions could harm business.
• Changes in Medicare payment rates for procedures involving iStent products were significant, impacting physician and facility fees.
• Research programs may fail to yield product candidates, affecting business prospects materially.
• Cybersecurity threats and incidents pose risks to information technology systems, potentially impacting operations.
• The company's ability to manufacture and ship products may be impacted by disruptions at its manufacturing locations, affecting revenue.
• Products may not receive regulatory approval, be profitable, or face competition with superior technologies.
• Supply/manufacturing disruptions impacting principal revenue-producing products could reduce gross margins and negatively impact operating results.
• Changes in foreign currency fluctuations may negatively impact revenue, gross margins, and operating income.
• The company's NDA submission for iDose TR was impacted, affecting future pipeline products. This change may delay approval.
• Products classified as drug-led drug-device combinations will require coordination by FDA's drug and device centers, potentially delaying approval.
• Failure to comply with data privacy laws could have a material adverse effect on business.
• The company faces risks related to unfavorable global and regional macroeconomic conditions, including inflation and labor shortages.
• Orphan drug exclusivity for Photrexa therapy expired in April 2023, impacting market competitiveness.
• Difficulty in scaling up manufacturing to meet increased demand may result in significant costs or lost revenue.
• Laws and regulations governing the company's U.S. operations were expanded, including the federal health care Anti-Kickback Statute.
• Global growth strategy faces challenges in managing foreign operations, impacting sales and operations.
• Cybersecurity incidents, service interruptions, or data corruption could disrupt operations and adversely affect business.
• The company's accumulated deficit was approximately $464 million as of December 31, 2023, impacting its financial condition and operations.
• Debt service obligations could limit cash flow, affecting the ability to pay debt obligations.
• Failure to raise funds to settle conversions of Convertible Notes may adversely affect financial condition.
• Failure to protect intellectual property could impair ability to compete effectively.